Giuseppe Testa
- Head of Neurogenomics Research Centre, Neurogenomica
- Research group leader, Testa Group
Giuseppe Testa è un medico, professore ordinario di Biologia Molecolare presso l’Università Statale di Milano e Direttore del Laboratorio di Epigenetica delle Cellule Staminali dell’Istituto Europeo di Oncologia. A Human Technopole il prof. Testa guida il Centro di Neurogenomica. All’interno del centro il suo laboratorio si occupa dei meccanismi molecolari alla base delle disabilità intellettive e dell’autismo.
Pubblicazioni
-
07/2021 - Taylor & Francis
Imbalanced autophagy causes synaptic deficits in a human model for neurodevelopmental disorders
Macroautophagy (hereafter referred to as autophagy) is a finely tuned process of programmed degradation and recycling of proteins and cellular components, which is crucial in neuronal function and synaptic integrity. Mounting evidence implicates chromatin remodeling in fine-tuning autophagy pathways. However, this epigenetic regulation is poorly understood in neurons. Here, we investigate the role in autophagy […]
-
07/2021 - Wiley
Exploiting epigenetic dependencies in ovarian cancer therapy
Ovarian cancer therapy has remained fundamentally unchanged for 50 years, with surgery and chemotherapy still the frontline treatments. Typically asymptomatic until advanced stages, ovarian cancer is known as “the silent killer.” Consequently, it has one of the worst 5-year survival rates, as low as 30%. The most frequent driver mutations are found in well-defined tumor suppressors, […]
-
05/2021 - Big Data & Society
Big Tech platforms in health research: Re-purposing big data governance in light of the General Data Protection Regulation’s research exemption
The emergence of a global industry of digital health platforms operated by Big Tech corporations, and its growing entanglements with academic and pharmaceutical research networks, raise pressing questions on the capacity of current data governance models, regulatory and legal frameworks to safeguard the sustainability of the health research ecosystem. In this article, we direct our […]
-
04/2021 - Nature Communications
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ
Cancer is characterized by pervasive epigenetic alterations with enhancer dysfunction orchestrating the aberrant cancer transcriptional programs and transcriptional dependencies. Here, we epigenetically characterize human colorectal cancer (CRC) using de novo chromatin state discovery on a library of different patient-derived organoids. By exploring this resource, we unveil a tumor-specific deregulated enhancerome that is cancer cell-intrinsic and […]
-
02/2021 - Wiley
Rethinking Human Embryo Research Policies
It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. The fourteen‐day limit was adopted as a compromise but subsequently has been considered an ethical line. Does it remain relevant in light of technological advances permitting […]
Previous page